1. Home
  2. PLUR

as of 12-12-2025 4:00pm EST

$3.08
$0.01
-0.32%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

Chart Type:
Time Range:
Founded: 2001 Country:
Israel
Israel
Employees: N/A City: HAIFA
Market Cap: 34.9M IPO Year: N/A
Target Price: $12.00 AVG Volume (30 days): 47.2K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.12 EPS Growth: N/A
52 Week Low/High: $3.02 - $7.13 Next Earning Date: 11-12-2025
Revenue: $1,326,000 Revenue Growth: 121.74%
Revenue Growth (this year): 97.38% Revenue Growth (next year): 293.97%

AI-Powered PLUR Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 60.56%
60.56%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Pluri Inc. News

PLUR Breaking Stock News: Dive into PLUR Ticker-Specific Updates for Smart Investing

All PLUR News

Share on Social Networks: